Immunovant (IMVT)

Executive Summary

Immunovant is a clinical-stage immunology company focused on developing anti-FcRn monoclonal antibodies to treat autoimmune diseases by reducing pathogenic IgG autoantibodies. The company's lead asset, batoclimab, is in Phase 3 for Thyroid Eye Disease (TED), with top-line data expected in mid-2026. A second-generation asset, IMVT-1402, is advancing in multiple Phase 2 trials for indications including Graves' disease, rheumatoid arthritis, and lupus. With a robust pipeline and a validated mechanism of action, Immunovant is positioned to address significant unmet needs in autoimmune diseases. The upcoming batoclimab readout is a critical near-term value driver, and positive results could support regulatory filings and expand the platform's potential.

Upcoming Catalysts (preview)

• Q3 2026Batoclimab Phase 3 TED Top-Line Data70% success
• Q1 2027IMVT-1402 Phase 2 Graves' Disease Data45% success
• Q4 2026Potential Batoclimab Regulatory Filing in TED50% success